


CDK9-IN-25

Cat. No.:	HY-155843
Molecular Formula:	C ₁₅ H ₁₆ FN ₅
Molecular Weight:	285.32
Target:	CDK; SARS-CoV; Virus Protease
Pathway:	Cell Cycle/DNA Damage; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC ₅₀ : 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC ₅₀ : 63.28 μM) ^[1] .
IC ₅₀ & Target	IC ₅₀ : 0.24 μM (CDK9), 63.28 μM (human Coronavirus 229E) ^[1]

REFERENCES

[1]. Alsouk AA, et al. New Imidazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches. Pharmaceuticals (Basel). 2023 Jul 18;16(7):1018.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA